- Home
- DAN vs ARQT Comparison
DAN vs ARQT Comparison
Compare DAN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAN | ARQT |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DAN | ARQT |
|---|---|---|
| Price | $32.45 | $22.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $35.00 | $31.86 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ 264.10 | 88.79 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $7,500,000,000.00 | $376,072,000.00 |
| Revenue This Year | $1.92 | $34.46 |
| Revenue Next Year | $3.60 | $29.77 |
| P/E Ratio | $50.41 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $10.11 | $11.86 |
| 52 Week High | $36.28 | $31.77 |
Technical Indicators
Market Signals| Indicator | DAN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 33.72 |
| Support Level | $28.30 | $13.34 |
| Resistance Level | $36.28 | $27.26 |
| Average True Range (ATR) | 1.22 | 0.99 |
| MACD | -0.38 | -0.23 |
| Stochastic Oscillator | 35.32 | 0.50 |
Price Performance
Historical ComparisonAbout DAN Dana Incorporated
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.